Zenas BioPharma (USA), LLC
Zenas BioPharma (USA), LLC
Explore linked clinical trials.6 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis | CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Recruiting | Phase 3 | 2026-10-07 | NCT07299019 | |
| A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis | CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Recruiting | Phase 3 | 2026-10-05 | NCT07067463 | |
| A Study of Obexelimab in Patients With Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Active, not recruiting | Phase 2 | 2026-08-18 | NCT06559163 | |
| A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease | Immunoglobulin G4-Related Disease, autoimmune disease, immune system disorder | Active, not recruiting | Phase 3 | 2026-02-04 | NCT05662241 | |
| A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Active, not recruiting | Phase 2 | 2025-11-17 | NCT06564311 | |
| A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre) | autoimmune hemolytic anemia, warm type | Active, not recruiting | Phase 3 | 2025-06-25 | NCT05786573 |